Table 4.
The Chance of Liver-Type Fatty Acid-Binding Protein ≥5.14 μg/g Creatinine—Results of the Univariate Regression
| OR | 95% CI | p | |
|---|---|---|---|
| Age | 1.00 | 0.94–1.07 | >0.05 |
| CD4 lymphocytes (cells/μl) | 1.15 | 0.88–1.50 | >0.05 |
| HIV viremia (copies/ml) | 0.71 | 0.12–4.21 | >0.05 |
| Anti-HCV | 3.29 | 0.80–13.41 | >0.5 |
| Years of treatment | 1.09 | 0.82–1.43 | >0.05 |
| Years on present treatment scheme | 0.99 | 0.84–1.16 | >0.05 |
| PIs/NNRTI | 0.57 | 0.17–1.93 | >0.05 |
| eGFR | 0.68 | 0.19–2.43 | >0.05 |
| Weight (kg) | 0.94 | 0.88–0.99 | 0.0247 |
According to this analysis weight was the only variable of statistical significance with respect to the occurrence of L-FABP≥5.14 μg/g creatinine.
OR, odds ratio; PIs, protease inhibitors; eGFR (estimated glomerular filtration rate; MDRD formula); HCV, hepatitis C virus; PIs, protease inhibitors; NNRTI, non nucleoside reverse transcriptase inhibitor.